{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T18:54:26Z","timestamp":1785610466221,"version":"3.56.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["15\/130\/20"],"award-info":[{"award-number":["15\/130\/20"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"crossref","award":["PG\/17\/64\/33205"],"award-info":[{"award-number":["PG\/17\/64\/33205"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic obstructive pulmonary disease (COPD) is associated with significant morbidity, mortality and healthcare costs. Beta blockers are well-established drugs widely used to treat cardiovascular conditions. Observational studies consistently report that beta blocker use in people with COPD is associated with a reduced risk of COPD exacerbations. The bisoprolol in COPD study (BICS) investigates whether adding bisoprolol to routine COPD treatment has clinical and cost-effective benefits. A sub-study will risk stratify participants for heart failure to investigate whether any beneficial effect of bisoprolol is restricted to those with unrecognised heart disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      BICS is a pragmatic randomised parallel group double-blind placebo-controlled trial conducted in UK primary and secondary care sites. The major inclusion criteria are an established predominant respiratory diagnosis of COPD (post-bronchodilator FEV\n                      <jats:sub>1<\/jats:sub>\n                      &lt;\u200980% predicted, FEV\n                      <jats:sub>1<\/jats:sub>\n                      \/FVC &lt;\u20090.7), a self-reported history of \u2265 2 exacerbations requiring treatment with antibiotics and\/or oral corticosteroids in a 12-month period since March 2019, age \u2265 40\u2009years and a smoking history \u2265 10 pack years. A computerised randomisation system will allocate 1574 participants with equal probability to intervention or control groups, stratified by centre and recruitment in primary\/secondary care. The intervention is bisoprolol (1.25\u2009mg tablets) or identical placebo. The dose of bisoprolol\/placebo is titrated up to a maximum of 4 tablets a day (5\u2009mg bisoprolol) over 4\u20137 weeks depending on tolerance to up-dosing of bisoprolol\/placebo\u2014these titration assessments are completed by telephone or video call. Participants complete the remainder of the 52-week treatment period on the final titrated dose (1, 2, 3, 4 tablets) and during that time are followed up at 26 and 52\u2009weeks by telephone or video call. The primary outcome is the total number of participant reported COPD exacerbations requiring oral corticosteroids and\/or antibiotics during the 52-week treatment period. A sub-study will risk stratify participants for heart failure by echocardiography and measurement of blood biomarkers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The demonstration that bisoprolol reduces the incidence of exacerbations would be relevant not only to patients and clinicians but also to healthcare providers, in the UK and globally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Current controlled trials\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.isrctn.com\/ISRCTN10497306\">ISRCTN10497306<\/jats:ext-link>\n                      . Registered on 16 August 2018\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-022-06226-8","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T13:02:48Z","timestamp":1649941368000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)"],"prefix":"10.1186","volume":"23","author":[{"given":"Seonaidh","family":"Cotton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0024-4887","authenticated-orcid":false,"given":"Graham","family":"Devereux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rekha","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gourab","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"De Soyza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shona","family":"Fielding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Gompertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Haughney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chim C.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"MacLennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"MacNee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"McMeekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas L.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyn","family":"Morice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Norrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorgen","family":"Vestbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadwiga","family":"Wedzicha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Lipworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"key":"6226_CR1","volume-title":"Chronic obstructive pulmonary disease in over 16\u2009s: diagnosis and management","author":"National Institute for Health and Care Excellence","year":"2018","unstructured":"National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16\u2009s: diagnosis and management. 2018. https:\/\/www.nice.org.uk\/guidance\/ng115. Accessed 23 Feb 2022."},{"key":"6226_CR2","volume-title":"Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach","author":"World Health Organisation","year":"2007","unstructured":"World Health Organisation. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. 2007. https:\/\/www.who.int\/gard\/publications\/GARD_Manual\/en\/. Accessed 23 Feb 2022."},{"issue":"2","key":"6226_CR3","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.05.020415","volume":"5","author":"D Adeloye","year":"2015","unstructured":"Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5(2):020415. https:\/\/doi.org\/10.7189\/jogh.05.020415.","journal-title":"J Glob Health"},{"issue":"11","key":"6226_CR4","doi-asserted-by":"publisher","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","volume":"3","author":"C Mathers","year":"2006","unstructured":"Mathers C, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. https:\/\/doi.org\/10.1371\/journal.pmed.0030442.","journal-title":"PLoS Med"},{"key":"6226_CR5","unstructured":"British Lung Foundation. Health statistics. 2015. http:\/\/statistics.blf.org.uk\/copd. Accessed 23 Feb 2022."},{"issue":"4","key":"6226_CR6","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1183\/09031936.00012408","volume":"32","author":"DM Mannino","year":"2008","unstructured":"Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962\u20139. https:\/\/doi.org\/10.1183\/09031936.00012408.","journal-title":"Eur Respir J"},{"issue":"4","key":"6226_CR7","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1378\/chest.128.4.2005","volume":"128","author":"F Holguin","year":"2005","unstructured":"Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest. 2005;128(4):2005\u201311. https:\/\/doi.org\/10.1378\/chest.128.4.2005.","journal-title":"Chest"},{"issue":"12","key":"6226_CR8","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1183\/09031936.97.10122794","volume":"10","author":"R Antonelli-Incalzi","year":"1997","unstructured":"Antonelli-Incalzi R, Fuso L, DeRosa M, Forastiere F, Rapiti E, Nardecchia B, et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 1997;10(12):2794\u2013800. https:\/\/doi.org\/10.1183\/09031936.97.10122794.","journal-title":"Eur Respir J"},{"issue":"1","key":"6226_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S0002-9343(02)01297-4","volume":"114","author":"DD Sin","year":"2003","unstructured":"Sin DD, Man JP, Man SF. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med. 2003;114(1):10\u20134. https:\/\/doi.org\/10.1016\/S0002-9343(02)01297-4.","journal-title":"Am J Med"},{"issue":"10","key":"6226_CR10","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/j.rmed.2006.01.026","volume":"100","author":"F Di Marco","year":"2006","unstructured":"Di Marco F, Verga M, Reggente M, Maria Casanova F, Santus P, Blasi F, et al. Anxiety and depression in COPD patients: the roles of gender and disease severity. Respir Med. 2006;100(10):1767\u201374. https:\/\/doi.org\/10.1016\/j.rmed.2006.01.026.","journal-title":"Respir Med"},{"issue":"18","key":"6226_CR11","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1093\/eurheartj\/ehi291","volume":"26","author":"FH Rutten","year":"2005","unstructured":"Rutten FH, Cramer MJ, Grobbee DE, Sachs AP, Kirkels JH, Lammers JW, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005;26(18):1887\u201394. https:\/\/doi.org\/10.1093\/eurheartj\/ehi291.","journal-title":"Eur Heart J"},{"issue":"1","key":"6226_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1183\/09031936.00044411","volume":"39","author":"A Macchia","year":"2012","unstructured":"Macchia A, Rodriguez Moncalvo JJ, Kleinert M, Comignani PD, Gimeno G, Arakaki D, et al. Unrecognised ventricular dysfunction in COPD. Eur Respir J. 2012;39(1):51\u20138. https:\/\/doi.org\/10.1183\/09031936.00044411.","journal-title":"Eur Respir J"},{"issue":"10","key":"6226_CR13","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1136\/thorax.57.10.847","volume":"57","author":"GC Donaldson","year":"2002","unstructured":"Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847\u201352. https:\/\/doi.org\/10.1136\/thorax.57.10.847.","journal-title":"Thorax"},{"issue":"5","key":"6226_CR14","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1164\/rccm.200408-1054OC","volume":"171","author":"GC Donaldson","year":"2005","unstructured":"Donaldson GC, Wilkinson TM, Hurst JR, Perera WR, Wedzicha JA. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171(5):446\u201352. https:\/\/doi.org\/10.1164\/rccm.200408-1054OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"6226_CR15","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1164\/ajrccm.157.5.9709032","volume":"157","author":"TA Seemungal","year":"1998","unstructured":"Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5):1418\u201322. https:\/\/doi.org\/10.1164\/ajrccm.157.5.9709032.","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"6226_CR16","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1136\/thx.2005.040527","volume":"60","author":"JJ Soler-Cataluna","year":"2005","unstructured":"Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925\u201331. https:\/\/doi.org\/10.1136\/thx.2005.040527.","journal-title":"Thorax"},{"key":"6226_CR17","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/S0954-6111(03)80027-6","volume":"97","author":"M Britton","year":"2003","unstructured":"Britton M. The burden of COPD in the U.K.: results from the Confronting COPD survey. Respir Med. 2003;97:S71\u20139. https:\/\/doi.org\/10.1016\/S0954-6111(03)80027-6.","journal-title":"Respir Med"},{"issue":"11","key":"6226_CR18","doi-asserted-by":"publisher","first-page":"e113048","DOI":"10.1371\/journal.pone.0113048","volume":"9","author":"Q Du","year":"2014","unstructured":"Du Q, Sun Y, Ding N, Chen Y. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS One. 2014;9(11):e113048. https:\/\/doi.org\/10.1371\/journal.pone.0113048.","journal-title":"PLoS One"},{"issue":"10","key":"6226_CR19","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/archinternmed.2010.112","volume":"170","author":"FH Rutten","year":"2010","unstructured":"Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170(10):880\u20137. https:\/\/doi.org\/10.1001\/archinternmed.2010.112.","journal-title":"Arch Intern Med"},{"issue":"1","key":"6226_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/thoraxjnl-2015-207251","volume":"71","author":"SP Bhatt","year":"2016","unstructured":"Bhatt SP, Wells JM, Kinney GL, Washko GR Jr, Budoff M, Kim YI, et al. Dransfield MT. \u03b2-Blockers are associated with a reduction in COPD exacerbations. Thorax. 2016;71(1):8\u201314. https:\/\/doi.org\/10.1136\/thoraxjnl-2015-207251.","journal-title":"Thorax"},{"issue":"8","key":"6226_CR21","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1056\/NEJM199808203390801","volume":"339","author":"SS Gottlieb","year":"1998","unstructured":"Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. New Eng J Med. 1998;339(8):489\u201397. https:\/\/doi.org\/10.1056\/NEJM199808203390801.","journal-title":"New Eng J Med"},{"issue":"12","key":"6226_CR22","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.amjmed.2004.07.043","volume":"117","author":"DH Au","year":"2004","unstructured":"Au DH, Bryson CL, Fan VS, Udris EM, Curtis JR, McDonell MB, et al. Beta-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. Am J Med. 2004;117(12):925\u201331. https:\/\/doi.org\/10.1016\/j.amjmed.2004.07.043.","journal-title":"Am J Med"},{"issue":"may10 2","key":"6226_CR23","doi-asserted-by":"publisher","first-page":"d2549","DOI":"10.1136\/bmj.d2549","volume":"342","author":"PM Short","year":"2011","unstructured":"Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. Br Med J. 2011;342(may10 2):d2549. https:\/\/doi.org\/10.1136\/bmj.d2549.","journal-title":"Br Med J"},{"issue":"nov22 3","key":"6226_CR24","doi-asserted-by":"publisher","first-page":"f6650","DOI":"10.1136\/bmj.f6650","volume":"347","author":"JK Quint","year":"2013","unstructured":"Quint JK, Herrett E, Bhaskaran K, Timmis A, Hemingway H, Wedzicha JA, et al. Effect of beta blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. Br Med J. 2013;347(nov22 3):f6650. https:\/\/doi.org\/10.1136\/bmj.f6650.","journal-title":"Br Med J"},{"issue":"21","key":"6226_CR25","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/j.jacc.2011.02.020","volume":"57","author":"NM Hawkins","year":"2011","unstructured":"Hawkins NM, Petrie MC, Macdonald MR, Jhund PS, Fabbri LM, Wikstrand J, et al. Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists. J Am Coll Cardiol. 2011;57(21):2127\u201338. https:\/\/doi.org\/10.1016\/j.jacc.2011.02.020.","journal-title":"J Am Coll Cardiol"},{"issue":"9146","key":"6226_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"CIBIS-II Investigators","year":"1999","unstructured":"Investigators CIBIS-II, Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9\u201313. https:\/\/doi.org\/10.1016\/S0140-6736(98)11181-9.","journal-title":"Lancet"},{"key":"6226_CR27","volume-title":"British guideline on the management of asthma","author":"British Thoracic Society\/Scottish Intercollegiate Guidelines Network","year":"2019","unstructured":"British Thoracic Society\/Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. 2019. https:\/\/www.brit-thoracic.org.uk\/quality-improvement\/guidelines\/asthma\/. Accessed 23 Feb 2022."},{"key":"6226_CR28","doi-asserted-by":"publisher","unstructured":"Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;(Issue 4) Art. No.: CD003566. https:\/\/doi.org\/10.1002\/14651858.CD003566.pub2.","DOI":"10.1002\/14651858.CD003566.pub2"},{"key":"6226_CR29","volume-title":"Chronic heart failure in adults: diagnosis and management","author":"National Institute for Health and Care Excellence","year":"2018","unstructured":"National Institute for Health and Care Excellence. Chronic heart failure in adults: diagnosis and management. 2018. https:\/\/www.nice.org.uk\/guidance\/cg108. Accessed 23 Feb 2022."},{"key":"6226_CR30","volume-title":"Management of chronic heart failure","author":"Scottish Intercollegiate Guidelines Network (SIGN)","year":"2016","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN). Management of chronic heart failure. 2016. https:\/\/www.sign.ac.uk\/assets\/sign147.pdf. Accessed 23 Feb 2022."},{"key":"6226_CR31","volume-title":"Bisoprolol SmPC","author":"Electronic medicines compendium","year":"2018","unstructured":"Electronic medicines compendium. Bisoprolol SmPC. 2018. https:\/\/www.medicines.org.uk\/emc\/product\/3092\/smpc. Accessed 23 Feb 2022."},{"issue":"6","key":"6226_CR32","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/S0149-2918(99)80026-5","volume":"21","author":"KC Farmer","year":"1999","unstructured":"Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Therap. 1999;21(6):1074\u201390. https:\/\/doi.org\/10.1016\/S0149-2918(99)80026-5.","journal-title":"Clin Therap"},{"issue":"21","key":"6226_CR33","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.106.620039","volume":"114","author":"H Skali","year":"2006","unstructured":"Skali H, Pfeffer MA, Lubsen J, Solomon SD. Variable impact of combining fatal and nonfatal end points in heart failure trials. Circulation. 2006;114(21):2298\u2013304. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.620039.","journal-title":"Circulation"},{"issue":"2","key":"6226_CR34","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1183\/09031936.03.00068503a","volume":"21","author":"TJ Witek Jr","year":"2003","unstructured":"Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J. 2003;21(2):267\u201372. https:\/\/doi.org\/10.1183\/09031936.03.00068503a.","journal-title":"Eur Respir J"},{"issue":"3","key":"6226_CR35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"The EuroQol Group","year":"1990","unstructured":"The EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208. https:\/\/doi.org\/10.1016\/0168-8510(90)90421-9.","journal-title":"Health Policy"},{"key":"6226_CR36","unstructured":"The COPD Assessment Test. 2018. https:\/\/www.catestonline.org\/hcp-homepage.html. Accessed 23 Feb 2022."},{"issue":"12","key":"6226_CR37","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","volume":"363","author":"JR Hurst","year":"2010","unstructured":"Hurst JR, Vestbo J, Anzueto A, Locantore N, M\u00fcllerova H, Tal-Singer R, et al. Evaluation of COPD Longitudinally to Identify Predictive, Surrogate Endpoints. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128\u201338. https:\/\/doi.org\/10.1056\/NEJMoa0909883.","journal-title":"N Engl J Med"},{"issue":"6","key":"6226_CR38","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1183\/09031936.04.00014304","volume":"23","author":"BR Celli","year":"2004","unstructured":"Celli BR, MacNee W, ATS\/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper. Eur Respir J. 2004;23(6):932\u201346. https:\/\/doi.org\/10.1183\/09031936.04.00014304.","journal-title":"Eur Respir J"},{"key":"6226_CR39","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"11","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modelling valuations for health states. Med Care. 1997;11:1095\u2013108.","journal-title":"Med Care"},{"issue":"5","key":"6226_CR40","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1136\/thx.2010.156372","volume":"66","author":"JW Dodd","year":"2011","unstructured":"Dodd JW, Hogg L, Nolan J, Jefford H, Grant A, Lord VM, et al. The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. Thorax. 2011;66(5):425\u20139. https:\/\/doi.org\/10.1136\/thx.2010.156372.","journal-title":"Thorax"},{"issue":"3","key":"6226_CR41","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1183\/09031936.00102509","volume":"34","author":"PW Jones","year":"2009","unstructured":"Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline LN. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648\u201354. https:\/\/doi.org\/10.1183\/09031936.00102509.","journal-title":"Eur Respir J"},{"issue":"6","key":"6226_CR42","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1378\/chest.85.6.751","volume":"85","author":"DA Mahler","year":"1984","unstructured":"Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85(6):751\u20138. https:\/\/doi.org\/10.1378\/chest.85.6.751.","journal-title":"Chest"},{"issue":"8","key":"6226_CR43","doi-asserted-by":"publisher","first-page":"E70","DOI":"10.1164\/rccm.201908-1590ST","volume":"200","author":"BL Graham","year":"2019","unstructured":"Graham BL, Steenbruggen I, Barjaktarevic IZ, et al. Standardization of spirometry 2019 update an official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med. 2019;200(8):E70\u201388. https:\/\/doi.org\/10.1164\/rccm.201908-1590ST.","journal-title":"Am J Respir Crit Care Med"},{"issue":"sup 49","key":"6226_CR44","doi-asserted-by":"publisher","first-page":"s75","DOI":"10.1192\/bjp.190.5.s75","volume":"190","author":"B Barrett","year":"2007","unstructured":"Barrett B, Byford S. Collecting service use data for economic evaluation in DSPD populations. Br J Psychiatry. 2007;190(sup 49):s75\u20138.","journal-title":"Br J Psychiatry"},{"issue":"8","key":"6226_CR45","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2016;18(8):891\u2013975. https:\/\/doi.org\/10.1002\/ejhf.592.","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"6226_CR46","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1001\/jama.2018.14432","volume":"320","author":"G Devereux","year":"2018","unstructured":"Devereux G, Cotton S, Fielding S, McMeekin N, Barnes PJ, Briggs A, et al. Effect of theophylline as adjunct to inhaled corticosteroids on exacerbations in patients with chronic obstructive pulmonary disease: a randomized clinical trial. JAMA. 2018;320(15):1548\u201359. https:\/\/doi.org\/10.1001\/jama.2018.14432.","journal-title":"JAMA"},{"key":"6226_CR47","unstructured":"National Institute for Health and Care Excellence. 2013. https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781. Accessed 23 Feb 2022."},{"key":"6226_CR48","unstructured":"National Health Service Health Research Authority. 2021. https:\/\/www.hra.nhs.uk\/approvals-amendments\/managing-your-approval\/safety-reporting\/. Accessed 23 Feb 2022."},{"issue":"8","key":"6226_CR49","doi-asserted-by":"publisher","first-page":"e0255659","DOI":"10.1371\/journal.pone.0255659","volume":"16","author":"JS Alqahtani","year":"2021","unstructured":"Alqahtani JS, Oyelade T, Aldhahir AM, Mendes RG, Alghamdi SM, Miravitlles M, et al. Reduction in hospitalised COPD exacerbations during COVID-19: a systematic review and meta-analysis. PLoS One. 2021;16(8):e0255659. https:\/\/doi.org\/10.1371\/journal.pone.0255659.","journal-title":"PLoS One"},{"issue":"3","key":"6226_CR50","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1183\/09031936.00035909","volume":"37","author":"JK Quint","year":"2011","unstructured":"Quint JK, Donaldson GC, Hurst JR, Goldring JJP, Seemungal TR, Wedzicha JA. Predictive accuracy of patient-reported exacerbation frequency in COPD. Eur Respir J. 2011;37(3):501\u20137. https:\/\/doi.org\/10.1183\/09031936.00035909.","journal-title":"Eur Respir J"},{"issue":"24","key":"6226_CR51","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1056\/NEJMoa1908142","volume":"381","author":"MT Dransfield","year":"2019","unstructured":"Dransfield MT, Voelker H, Bhatt SP, Brenner K, Casaburi R, Come CE, et al. Metoprolol for the prevention of acute exacerbations of COPD. New Eng J Med. 2019;381(24):2304\u201314. https:\/\/doi.org\/10.1056\/NEJMoa1908142.","journal-title":"New Eng J Med"},{"issue":"3","key":"6226_CR52","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/sj.bjp.0706048","volume":"144","author":"JG Baker","year":"2005","unstructured":"Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol. 2005;144(3):317\u201322. https:\/\/doi.org\/10.1038\/sj.bjp.0706048.","journal-title":"Br J Pharmacol"},{"issue":"5","key":"6226_CR53","doi-asserted-by":"publisher","first-page":"453","DOI":"10.18926\/AMO\/55446","volume":"71","author":"A Taniguchi","year":"2017","unstructured":"Taniguchi A, Miyahara N, Oda N, Morichika D, Ichihara E, Oze I, et al. Protective effects of bisoprolol against acute exacerbation in moderate-to-severe chronic obstructive pulmonary disease. Acta Med Okayama. 2017;71(5):453\u20137. https:\/\/doi.org\/10.18926\/AMO\/55446.","journal-title":"Acta Med Okayama"},{"issue":"1","key":"6226_CR54","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13063-019-3907-1","volume":"21","author":"J Sundh","year":"2020","unstructured":"Sundh J, Magnuson A, Montgomery S, Andell P, Rindler G, Fr\u00f6bert O. Beta-blockers to patients with chronic obstructive pulmonary disease (BRONCHIOLE) - Study protocol from a randomized controlled trial. Trials. 2020;21(1):123. https:\/\/doi.org\/10.1186\/s13063-019-3907-1.","journal-title":"Trials"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06226-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06226-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06226-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T22:07:05Z","timestamp":1650060425000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06226-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6226"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06226-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1271797\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]},"assertion":[{"value":"31 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial has received a favourable opinion from Scotland A Research Ethics Committee (ref\n                      \n                      \/SS\/0033, 22\/05\/2018) and the Medicines and Healthcare products Regulatory Agency (MHRA) (EudraCT 2017-002779-24, CTA 21583\/0222\/001-0001, 12\/06\/2018). All participants provide written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"A copy of the participant information leaflet and consent form is available as a\n                      \n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The study is funded by the NIHR Health Technology Assessment. The chief investigator, study grant holders and protocol authors have no financial or competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"307"}}